Lapatinib, it turns out, also inhibits the activity of a protein called the epidermal growthfactorreceptor, which has been found to be important for stem-cell proliferation.
The public has mostly focused on Erbitux's ability to slow tumor growth by blocking epidermal growthfactorreceptor, a key growth-promoting protein that is overabundant in many cancer cells.